The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes
No relationship between apoA-V and postheparin plasma lipolytic activity
- Juhani Kahri, MD, PHD1,
- Jamila Fruchart-Najib, PHD2,
- Niina Matikainen, MD, PHD1,
- Jean-Charles Fruchart, MD, PHD2,
- Juha Vakkilainen, MD, PHD1 and
- Marja-Riitta Taskinen, MD1
- 1Division of Cardiology, Helsinki University Hospital, Biomedicum, Helsinki, Finland
- 2Department of Atherosclerosis, INSERM UR 545, Pasteur Institute of Lille, University of Lille, Lille, France
- Address correspondence and reprint requests to Prof. Marja-Riitta Taskinen, University of Helsinki, Biomedicum, Haartmaninkatu 8, P.O. Box 700, FIN-00029 HUS, Helsinki, Finland. E-mail: marja-riitta.taskinen{at}helsinki.fi
- apo, apolipoprotein
- IAUC, incremental area under the curve
- LPL, lipoprotein lipase
- TRL, triglyceride-rich lipoprotein
Postprandial lipemia is a distinct feature of diabetic dyslipidemia and may partly explain the atherogeneity of the lipid profile in type 2 diabetes (1). Several genetic factors contribute to the elevation of triglyceride-rich lipoproteins (TRLs). The role of apolipoprotein (apo)C-III as a regulator of TRL metabolism is well documented (2). Recently, apoA-V has been identified as a novel regulator of triglyceride metabolism. When the human APOA5 gene was expressed in transgenic mice, plasma triglyceride concentration was decreased by 70%, whereas apoA5 gene knockout mice had fourfold elevation of plasma triglyceride levels (3). Inherited apoA-V deficiency results in severe hypertriglyceridemia in humans (4). A mutation in the APOA5 gene causes hypertriglyceridemia due to decreased lipoprotein lipase (LPL) mass and activity (5). Thus, previous studies have proposed that apoA-V decreases triglycerides by stimulating lipolysis.
The present study focused on the response of apoA-V and apoC-III during postprandial lipemia and the associations between apoA-V and apoC-III and postheparin plasma LPL and hepatic lipase activities in type 2 diabetes.
RESEARCH DESIGN AND METHODS—
The present study cohort was comprised of 39 men and 8 women with type 2 diabetes who were enrolled in the previously published nateglinide study with the same inclusion and exclusion criteria (6). A total of 17 patients were treated with diet alone, 20 with sulfonylurea, and 11 with metformin. The …
